Financial Review: Calmare Therapeutics (CTTC) and Endologix (ELGX)
Calmare Therapeutics (OTCMKTS:CTTC) and Endologix (NASDAQ:ELGX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.
This is a breakdown of recent ratings and recommmendations for Calmare Therapeutics and Endologix, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Valuation and Earnings
This table compares Calmare Therapeutics and Endologix’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Calmare Therapeutics||$1.11 million||1.23||-$3.82 million||N/A||N/A|
|Endologix||$181.16 million||0.33||-$66.40 million||($0.48)||-1.21|
Calmare Therapeutics has higher earnings, but lower revenue than Endologix.
Risk & Volatility
Calmare Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Comparatively, Endologix has a beta of 0.56, meaning that its share price is 44% less volatile than the S&P 500.
Institutional & Insider Ownership
0.5% of Calmare Therapeutics shares are held by institutional investors. Comparatively, 74.3% of Endologix shares are held by institutional investors. 17.5% of Calmare Therapeutics shares are held by company insiders. Comparatively, 1.4% of Endologix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
This table compares Calmare Therapeutics and Endologix’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Calmare Therapeutics beats Endologix on 7 of the 11 factors compared between the two stocks.
Calmare Therapeutics Company Profile
Calmare Therapeutics Incorporated, a medical device company, develops and commercializes products and technologies for chronic neuropathic pain and wound care affliction patients in the United States. Its flagship medical device is Calmare Pain Therapy Device, a non-invasive and non-addictive modality for the treatment of chronic and neuropathic pain. The company was formerly known as Competitive Technologies, Inc. and changed its name to Calmare Therapeutics Incorporated in August 2014. Calmare Therapeutics Incorporated was founded in 1968 and is based in Fairfield, Connecticut.
Endologix Company Profile
Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. It offers minimally-invasive endovascular repair (EVAR) products, including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the ovation abdominal stent graft system. The company also provides endovascular sealing (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, it offers proximal aortic extensions and limb extensions which allows physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. The company offers its EVAR products under Ovation, Powerlink System, IntuiTrak, AFX, VELA Proximal Endograft brand names; and EVAS products under the Nellix EVAS system brand name. It sells its products through direct sales force, network of agents, and independent distributors or agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.
Receive News & Ratings for Calmare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calmare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.